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A set of seven caged gadolinium complexes were used as
vectors for introducing the chelated Gd3+ ion into protein
crystals in order to provide strong anomalous scattering for de
novo phasing. The complexes contained multidentate ligand
molecules with different functional groups to provide a panel
of possible interactions with the protein. An exhaustive
crystallographic analysis showed them to be nondisruptive to
the diffraction quality of the prepared derivative crystals, and
as many as 50% of the derivatives allowed the determination
of accurate phases, leading to high-quality experimental
electron-density maps. At least two successful derivatives
were identified for all tested proteins. Structure refinement
showed that the complexes bind to the protein surface or
solvent-accessible cavities, involving hydrogen bonds, electro-
static and CH– interactions, explaining their versatile
binding modes. Their high phasing power, complementary
binding modes and ease of use make them highly suitable as
a heavy-atom screen for high-throughput de novo structure
determination, in combination with the SAD method. They
can also provide a reliable tool for the development of new
methods such as serial femtosecond crystallography.
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1. Introduction
Despite the growing number of available structures allowing
the phases of the structure factors to be obtained by molecular
replacement, experimental phases remain essential in the
absence of suitable homologous structures. Unless the protein
contains endogenous anomalous scatterers, introducing a
heavy atom (HA) or anomalous scatterer into the inherently
fragile protein crystals without perturbing diffraction quality
remains one of the bottlenecks of protein structure determi-
nation. Phasing methods based on anomalous scattering have
the advantage that no isomorphous derivatives are required.
Table 1 shows a summary of the compounds used for experi-
mental phasing. Using selenomethionyl protein crystals for
MAD phasing is the most used approach (Hendrickson et al.,
1990; Dauter & Nagem, 2002), but expression and crystal-
lization is not always straightforward and, although possible
(Doublie´, 2007), is not yet commonly applied in eukaryotic
expression. For a review of derivatization methods using
classical HA compounds, see Garman &Murray (2003). Sulfur
SAD (Hendrickson & Teeter, 1981; Ramagopal et al., 2003b)
is limited to relatively well diffracting protein crystals that
contain a large proportion of Met or Cys residues, as it
provides a comparatively small anomalous signal, and faces
technical problems inherent to the use of softer X-rays. Site-
specific radiation damage can be exploited as an additional
source of phase information (Ravelli et al., 2003; Schiltz et al.,
2004). The search for an adequate HA derivative often
remains a tedious and random stage, as the classical
compounds bind only to specific motifs or are deleterious to
the crystal quality. Therefore, the development of reliable and
straightforward methods for obtaining heavy-atom derivatives
remains an important challenge.
The anomalous phasing power of a derivative is propor-
tional to the imaginary part of the atomic scattering factor f 00
of the HA and to the occupancy of its binding site. Lanthanide
(Ln) atoms provide high anomalous scattering, owing to a
white line, with f 0 0 ’ 28 e, in their LIII absorption edge, which
is accessible using synchrotron radiation for certain lantha-
nides (for Gd the LIII wavelength is 1.7 A˚). Several Lns also
provide high anomalous signal at a home source (for Gd, f 00
for Cu K is 12 e). Nevertheless, the use of Ln salts is limited
to proteins with calcium-binding sites owing to otherwise
insufficient binding. In order to overcome this limited binding
spectrum, we propose the use of a set of seven caged gadoli-
nium complexes composed of multidentate ligand molecules,
each chelating one Gd3+ ion, containing different functional
groups to provide a panel of possible interactions with the
protein of interest (Fig. 1). Previously, several of these
complexes have been used for experimental phasing using a
number of test proteins (Girard, Stelter, Anelli et al., 2003;
Girard et al., 2002; Girard, Stelter, Vicat et al., 2003).
Furthermore, to our knowledge, the use of the complexes has
allowed the determination of at least six new structures (Jeudy
et al., 2005; Hermoso et al., 2005; Gras et al., 2007; Ma´rquez et
al., 2006; Molina, Gonza´lez et al., 2009; Pe´rez-Dorado et al.,
2010). Their compatibility with lipidic mesophases as a crys-
tallization medium has been ascertained (Girard et al., 2004).
Very recently, the Gd-HPDO3A complex, also called gado-
teridol, was used in the first reported de novo phasing by serial
femtosecond crystallography (Barends et al., 2014). In the
particular cases of lysozyme and Streptococcus pneumoniae
choline-binding protein F (CbpF), the binding modes of
several complexes have been determined (Girard et al., 2002;
Molina, Stelter et al., 2009). In these cases, binding mainly
occurred via hydrophobic CH– interactions between the
cyclen macrocycle of the complex and aromatic tryptophan
side chains present in the active site of lysozyme and in the
choline-binding motifs (CBMs) of CbpF. On the other hand,
the complexes displayed a very different binding behaviour
with urate oxidase (Girard, Stelter, Anelli et al., 2003), indi-
cating that binding of the complexes occurs via different
modes depending on the protein.
In this study, we have carried out, for the first time, a
statistically relevant analysis of complex binding and phasing
power for a large number of derivatives obtained with various
proteins. Using our range of seven test proteins, phasing was
successful for more than 50% of the derivatives (25 out of 44)
and for at least two of the complexes for each of the tested
proteins. We analysed the structures of the different
complexes bound to the proteins, which revealed their distinct,
complementary binding modes, explaining their unequal
binding behaviour with different proteins. Our results high-
light the advantage of accurate experimental electron-density
research papers
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Table 1
Examples of heavy-atom compounds or endogenous scatterers used in anomalous phasing methods.
Shown are typical anomalous differences and binding modes. Certain derivatives are also suitable for isomorphous replacement methods. abs, absorption edge
wavelength; NH, typical number of anomalous scatterers per 100 amino-acid residues; qj, typical binding-site occupancy; F
/F, theoretical anomalous signal
(equation 1).
Type Compounds
abs
(A˚)
f 0 0
(e) NH, qj
F/F
(%) Binding mode
SelenoMet Selenium† 0.98 3.8 2, 1 4.1 Selenomethionine
Halide compounds‡ Bromine 0.92 3.8 3, 0.5 2.5 Binding in solvation shell. Arg, Lys. Also as brominated
nucleic acids§ or iodination of tyrosines with
N-iodosuccinimide.
Iodine triiodide} 1.54†† 6.8 3, 0.5 4.5
I3C‡‡§§ (or B3C) 1.54†† 6.8 6, 0.8 10.2 Hydrogen bonds through functional carboxylate and amine
groups
Noble gases Xe 1.54†† 7.3 3, 0.3 2.9 Pressure derivatization. Binding in hydrophobic cavities.
Kr 0.86 3.8 3, 0.3 1.5
Weak endogenous scatterers}} S 2.0†† 0.90 4, 1 1.4 Endogenous
1.54†† 0.56 0.85
P 2.0†† 0.70 }} 2.7
1.54†† 0.43 1.7
Cl 2.0†† 1.1 2, 0.8 0.96
Endogenous scatterers Mn 1.89 9.7 1, 1 7.3
Fe 1.74 4.5 1, 1 3.4
Classical heavy-atom salts†††,
e.g. magic seven
UO2(C2H3O2)2, K3UO2F5,
lanthanides
1.54†† 13.4 2, 0.3 4.3 Class A metals: charge interactions with electronegative
protein residues, e.g. carboxylate of Glu/Asp. Lns in Ca
sites.
K2PtCl4, K2HgI4, HgCl2,
PCMBS‡‡‡, KAu(CN)2, Pb, Tl
Pt: 1.1 10 1, 0.5 3.9 Class B metals: covalent binding to soft ligands (Cys, His,
Met) or interaction with hydroxyl groups.Hg: 1.0 10 1, 1 7.7
Caged, cyclen-based Ln
complexes
Gd 1.71 28 2, 0.5 21.3 Hydrogen bonds through functional carboxylate and amine
groups, water network, CH– interaction with aromatic
residues, ionic interaction of Gd3+ ion and carboxylates.
Gd 1.54†† 12 2, 0.5 6.4
Yb 1.39 28
Eu 1.54†† 12
† Hendrickson et al. (1990). ‡ Dauter & Dauter (2007). } Evans & Bricogne (2002). †† Suitable wavelength if the absorption edge is inaccessible. § Ennifar et al.
(2002). ‡‡ 5-Amino-2,4,6-triiodoisophthalic acid. §§ Beck et al. (2008). }} 10 P atoms in 290 atoms. ††† Blundell & Johnson (1976). ‡‡‡ p-Chloromercuriphenylsulfonic
acid.
maps for straightforward structure determination and for the
direct identification of bound ligands.
The high success rate of this set of complexes is owing to
their ease of use, their versatile binding properties and their
high phasing power, making them very suitable as a heavy-
atom screen, in addition to more traditional heavy-atom
compounds, for solving new, challenging structures. They also
constitute a powerful tool to develop cutting-edge crystallo-
graphic methods, such as the emerging serial femtosecond
crystallography on microcrystals. Finally, the complexes are
now commercially available.
2. Methods
2.1. Gd complexes and proteins
The complexes were obtained as described in Girard,
Stelter, Anelli et al. (2003). Gd-HPDO3A, Gd-DO3A, Gd-
DOTMA and Gd-DOTA-BOM were kindly provided by
Bracco Imaging SpA, Milan, Italy and solutions of Gd-DOTA,
Gd-DTPA and Gd-DTPA-BMA by Professor J.-F. Le Bas,
CHU-Hoˆpital Nord, Grenoble, France. The complexes are
very stable, nontoxic and have a high solubility in water of
above 1M, except for Gd-DOTA-BOM, which has a solubility
of 0.6M. They are about 8.5–10 A˚ in diameter. For thermo-
dynamic characterizations, see Bianchi et al. (2000) and Aime
et al. (1996). Originally used for medical imaging, the Gd
complexes generally display a comparatively weak affinity for
biological molecules.
Europium and ytterbium complexes of DOTA, DO3A,
HPDO3A and DTPA-BMA, as well as Gd-HPDO3A, are now
available as part of a Lanthanide Phasing Kit distributed by
NatX-ray (http://www.natx-ray.com). Complexes with other
Lns show the same binding behaviour with proteins as the
corresponding Gd complexes (Girard, Anelli et al., 2003).
Europium has very similar anomalous scattering properties
as gadolinium. Ytterbium complexes are very well suited for
synchrotron experiments, with an LIII wavelength of 1.39 A˚,
but less so for in-house data collection, with an f 0 0 for Cu K of
5 e.
The test proteins were chosen to cover a large range of
crystallization conditions based on different salts, PEGs or
MPD and a variable pH between pH 4.5 and 9: Aspergillus
flavus urate oxidase, Streptomyces rubiginosus glucose
isomerase, Thaumatococcus daniellii thaumatin, hen egg-white
lysozyme, Escherichia coli hypothetical protein YggV and
E. coli YeaZ. For the purpose of comparison and complete-
ness, we include our previous results with S. pneumoniae CbpF
(Molina, Stelter et al., 2009).
A. flavus urate oxidase was kindly provided by Sanofi
Synthe´labo. Hen egg-white lysozyme was purchased from
Boehringer, T. daniellii thaumatin was purchased from Sigma,
S. rubiginosus glucose isomerase was purchased from
Hampton Research and E. coli YeaZ and native crystals of
E. coli YggV were produced by the IGS laboratory. Produc-
tion of S. pneumoniae CbpF has been described previously
(Molina et al., 2007).
2.2. Crystallization
All proteins were used to prepare derivative crystals with
seven Gd complexes, except for glucose isomerase and YeaZ,
for which six and three complexes were tested, respectively.
The proteins were crystallized by the hanging-drop vapour-
diffusion technique. Crystallization conditions were optimized
based on the known conditions. Urate oxidase crystals were
obtained by mixing 4 ml protein solution at a concentration of
11.3 mg ml1 with 2 or 2.5 ml reservoir solution consisting of
75 mM Tris pH 8.5, 6–15% PEG 3350 (Bonnete´ et al., 2001).
Crystallization trays were prepared and stored at 281 K.
Lysozyme crystals were obtained by mixing the protein at
a concentration of 40 mg ml1 with a reservoir solution
consisting of 50 mM sodium acetate pH 4.5, 0.8–1.2M NaCl
at 293 K. Thaumatin crystals were obtained by mixing 6 ml
protein solution at a concentration of 50 mg ml1 with 4 ml
reservoir solution consisting of 100 mM ADA pH 6.6, 0.6–
0.9M disodium potassium tartrate, 0–5% ethylene glycol at
293 K (Ko et al., 1994). Glucose isomerase crystals were
obtained by mixing the protein at a concentration of
30 mg ml1 with a reservoir solution consisting of 50 mM Tris
pH 7, 9–14% MPD, 50 mMMgCl2 at 293 K (Ramagopal et al.,
2003a). Native crystals of YggV crystallized in 0.1M Bicine
pH 9.0, 33.3–38% ammonium sulfate, 5% glycerol at 293 K.
Crystals of YeaZ were obtained by mixing 1 ml 17 mg ml1
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Figure 1
Ligands of the seven Gd complexes used in this study. The ligands are derivatives of the tetraazacyclododecane (cyclen) macrocycle (a, b) or linear (c).
(a) R1 = H, DO3A; R1 = CH2COO
, DOTA; R1 = CH2CHCH3COO
, HPDO3A. (b) R2 = CH3, DOTMA; R2 = CH2OCH2C6H5, DOTA-BOM. (c) R3 =
COO, DTPA; R3 = CONHCH3, DTPA-BMA. The Gd complexes of DO3A, HPDO3A and DTPA-BMA are electrically neutral, those of DOTA,
DOTMA and DOTA-BOM bear one negative charge and that of DTPA bears two negative charges. (d) The DO3A ligand chelating the Gd3+ ion
(magenta sphere). In solution, the enneacoordination is completed by two water molecules (red spheres). Blue and grey dashed lines indicate
interactions of the ion with the ligand and water molecules, respectively.
protein solution with 0.5 ml reservoir solution consisting of
0.1M sodium acetate buffer pH 4.7–5.5, 4–8% PEG 8000,
0.2M NaCl, 10–20% glycerol (Jeudy et al., 2005). Crystals of
CbpF were grown using a protein solution consisting of
140 mM choline chloride, 20 mM Tris pH 8.0 and 3.9 mg ml1
protein and a reservoir solution consisting of 0.01M NiCl2,
20% PEG MME 2K, 0.1M Tris pH 8.5 (Molina et al., 2007).
Derivative crystals were obtained by co-crystallization or by
soaking the native protein crystals using the complexes at a
concentration of 50–100 mM (Supplementary Table S11). In
most cases derivative crystals could be obtained by either
method, and in these cases no difference in the binding
behaviour of the complexes was observed. Lysozyme-deriva-
tive crystals could only be obtained by co-crystallization
because the crystals did not support soaking, which is probably
owing to the atypically low solvent content and small solvent
channels of lysozyme crystals preventing diffusion of the
complexes. For co-crystallization, the Gd-complex solution
was added to the drop in order to obtain the final complex
concentration. In certain cases, the complexes affected the
protein solubility, for which we had to compensate by
increasing or decreasing the precipitant concentration of the
crystallization buffer (Supplementary Table S1). We found
that whenever this was the case the complex actually bound to
the protein. Thus, observed modification of protein solubility
can be a useful indicator of successful binding, even if in our
hands binding did not necessarily modify the crystallization
conditions.
For soaking, the native crystals were transferred to a drop of
mother liquor containing, in addition, the indicated concen-
tration of the Gd complex and 1–5 mg ml1 protein. Deriva-
tive crystals of YggV and YeaZ were exclusively obtained by
soaking previously obtained native crystals. Typical soaking
times were about 45 min to 1 h (Supplementary Table S1).
However, this could vary depending on the binding affinity
and the crystal size. Thus, for YeaZ it was necessary to increase
the soaking time to 6 h, while for CbpF soaking times were
exceptionally short, with 10 s leading to optimum binding,
owing to the higher than usual affinity of the complexes for the
CBMs of the protein. Similar short soaking times had also
been sufficient for Gd-HPDO3A binding to the S. pneumoniae
phosphorylcholine esterase Pce (Lagartera et al., 2005).
After the desired soaking time or when the co-crystals
reached the desired size, the derivative crystals were briefly
(10 s) soaked in the cryoprotecting solution and cooled in
liquid nitrogen or a gaseous nitrogen stream. Solutions for
cryoprotection correspond to the crystallization solution
without any Gd complex supplemented with 25–30% PEG 400
for urate oxidase and lysozyme crystals, 25% ethylene glycol
for thaumatin crystals, 30% MPD for glucose isomerase
crystals and 17% glycerol for CbpF crystals. The YggV and
YeaZ crystallization solutions were suitable as cryoprotectants.
Complexes that were observed to bind well to lysozyme,
urate oxidase and thaumatin were subsequently used at a
concentration of 300 mM in order to increase the occupancy of
the complex binding sites and to refine the structure of the
bound complex (Supplementary Table S1).
2.3. Data collection and processing
For all derivatives, redundant diffraction data were
collected (Supplementary Table S2) at 100 K. Initial data were
collected using Cu K radiation from a Rigaku RU-200
rotating-anode X-ray generator equipped with a Supper 7600
double-mirror system or a Nonius rotating-anode generator
equipped with an Osmic focusing system on a MAR300 or a
MAR345 imaging-plate detector, respectively. For derivatives
where significant complex binding was detected, additional
data were collected using synchrotron radiation on the
BM30A beamline at the European Synchrotron Radiation
Facility (ESRF), Grenoble, France at the f 00 maximum of the
Gd LIII absorption edge. At the time, owing to the detector
size and distance, the resolution was limited to 2.7 A˚ at the
wavelength corresponding to the Gd absorption edge. Addi-
tional data to the highest possible resolution were collected at
a shorter wavelength for derivatives with a high anomalous
signal, in anticipation of subsequent structure refinement of
the bound complex molecules. These additional data were
collected on the ESRF BM30A or ID29 beamlines. Diffraction
data were integrated using XDS (Kabsch, 2010) and were
scaled with SCALA, and the solvent content was estimated
by TRUNCATE (Winn et al., 2011). A summary of the data-
collection parameters and processing statistics is given in
Supplementary Table S2. The binding of the anomalous scat-
terers in the derivative crystals was estimated after reducing
and scaling complete diffraction data sets using the corre-
sponding statistical indicators of the data integration and
scaling program (snorm/sano in XDS and Rano in SCALA) and
via inspection of the anomalous difference Patterson map (an
example is shown in Supplementary Fig. S1).
Although concentrations of heavy atoms in the range of
those used here in protein crystals are supposed to lead to
increased radiation damage (Murray et al., 2004), we did not
observe such an effect with our Gd complexes, even for data
collected at the Gd absorption edge. We presume that the cage
around the heavy atoms formed by the respective ligands
might protect the protein from the effects of X-ray absorption
by the Ln atom. On the high-intensity beamline ID29, we
could observe some radiation damage characterized by a loss
of reflections at high resolution, but not more than would be
expected for native crystals.
2.4. Phasing and analysis
The initial coordinates of the bound Gd atoms were iden-
tified using SHELXD (Sheldrick, 2008) and SnB (Weeks &
Miller, 1999). SAD or MAD phasing was carried out using
SHARP (Bricogne et al., 2003) and density modification was
carried out using SOLOMON (Abrahams, 1997) and DM
(Cowtan & Main, 1996), both of which are accessible via the
SHARP interface. For each derivative, phasing was typically
carried out using two data sets: one data set at high resolution
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1 Supporting information has been deposited in the IUCr electronic archive
(Reference: TZ5054).
with a relatively weak anomalous signal (f 00 ’ 6 e) and one
data set collected at maximum f 00 limited in resolution to
2.7 A˚. The density-modification step allowed the extension of
the experimental phases to high resolution. A summary of the
phasing statistics is given in Supplementary Table S3.
As a first criterion, the outcome of the phasing can be
estimated based on phasing statistics, including the figure of
merit before and after density modifi-
cation. Eventually, we only considered
as successful the derivatives which led
to easily interpretable experimental
electron-density maps that permitted
straightforward model building.
Because map quality is not only influ-
enced by the accuracy of the phases,
once the refined model is available a
more meaningful measure of the
phasing quality is the complex correla-
tion coefficient between the observed
and the calculated structure factor as a
function of resolution. Phasing results
are summarized in Table 2.
2.5. Structure refinement
For all 24 derivatives that allowed
determination of the complex binding
sites, the structure of the protein and
the positions, occupancies and B factors
of the Gd atoms were refined. Refine-
ment statistics are given in Table 3. All
derivative structures were mostly
isomorphous with the native structures
and did not require major adjustment of
the protein model. Refinement of the
ligand moieties of the bound complexes
was not always possible. Indeed,
binding-site occupancies of about 0.2–
0.5 can provide sufficient anomalous
signal for phasing, but the electron
density of the ligand is generally too
poor to identify and refine its orientation. The models of the
ligand molecules could be refined for 21 derivatives in total
(Table 3).
The models of the proteins and bound gadolinium
complexes were refined using CNS (Bru¨nger et al., 1998)
against the data sets with the highest Gd-site occupancies and
resolution. For derivatives where phases were obtained by
research papers
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Table 2
Phasing results obtained for 44 different derivatives.
The average solvent content of the crystals is indicated for all proteins. — indicates no significant complex binding; FOM, figure of merit after density modification;
F/F, theoretical anomalous signal, as in Table 1, calculated for f 0 0 = 28 e and refined anomalous binding-site occupancies qj (Table 3).
Urate oxidase Glucose isomerase Thaumatin YGGV Lysozyme CbpF YeaZ
Solvent content (%) 52 48 48 49 28 58 48
FOM
F/F
(%) FOM
F/F
(%) FOM
F/F
(%) FOM
F/F
(%) FOM
F/F
(%) FOM
F/F
(%) FOM
F/F
(%)
Gd-DO3A 0.77 3.9 0.86 6.4 — — 0.83 6.1 0.75 14.9 0.84 10.3 0.83 7.0
Gd-HPDO3A — — — — — — — — 0.91 16.0 0.86 11.2
Gd-DTPA-BMA 0.92 10.0 — — 0.90 6.3 — — — — 0.80 3.4 — —
Gd-DOTA — — — — 0.88 5.1 — — 0.88 11.8 0.78 5.5
Gd-DOTMA 0.86 8.5 — — — — 0.90 7.1 — — 0.77 5.0 0.82 5.6
Gd-DTPA — — 0.88 3.1 0.91 4.8 — — — — 0.82 7.7
Gd-DOTA-BOM — — 0.91 9.2 0.79 6.8 0.75 8.9 0.81 7.6
Table 3
Refinement statistics for all derivatives that allowed experimental phasing.
No. of binding sites, number of complex binding sites; No. of refined sites, number of refined complex
molecules.
Complex
No. of
binding
sites
No. of
refined
sites Binding-site occupancies R/Rfree
Resolution
(A˚)
Urate oxidase
Gd-DOTMA 3 1 1.00, 0.29, 0.21 0.20/0.21 1.35
Gd-DTPA-BMA 3 3 0.92, 0.48, 0.70 0.19/0.20 1.45
Gd-DO3A 10 0 0.26, 0.21, 0.19, 0.17, 0.14, 0.14,
0.11, 0.08, 0.07, 0.05
0.22/0.23 1.45
Lysozyme
Gd-HPDO3A 2 2 1.00, 0.87 0.17/0.20 1.53
Gd-DOTA-BOM 1 1 0.74 0.22/0.25 1.53
Gd-DOTA 2 2 0.82, 0.53 0.19/0.19 1.54
Gd-DO3A 4 2 0.96, 0.69, 0.31, 0.18 0.23/0.25 1.54
Thaumatin
Gd-DOTA-BOM 2 2 0.84, 0.48 0.20/0.20 1.45
Gd-DTPA-BMA 1 1 0.66 0.19/0.20 1.45
Gd-DOTA 1 1 0.54 0.20/0.20 1.45
Gd-DTPA 1 1 0.50 0.19/0.20 1.45
YGGV
Gd-DOTMA 3 1 0.66, 0.25, 0.17 0.28/0.33 2.70
Gd-DOTA-BOM 3 0 0.47, 0.39, 0.34 0.31/0.38 2.68
Gd-DO3A 4 1 0.51, 0.25, 0.20, 0.17 0.32/0.37 2.68
YeaZ
Gd-DOTMA 8 1 0.66, 0.42, 0.36, 0.20, 0.17, 0.17 0.22/0.25 2.3
Gd-DO3A 6 2 0.74, 0.67, 0.33, 0.30, 0.29, 0.18 0.23/0.29 2.7
Glucose isomerase
Gd-DTPA 1 1 0.45 0.19/0.20 1.45
Gd-DO3A 6 3 0.56, 0.56, 0.37, 0.24, 0.15, 0.10 0.21/0.21 1.44
CbpF
Gd-HPDO3A 5 4 0.87, 0.72, 0.66, 0.60, 0.13 0.21/0.24 2.17
Gd-DO3A 6 3 0.83, 0.66, 0.63, 0.30, 0.29, 0.28 0.22/0.25 2.17
Gd-DOTA-BOM 4 0 0.95, 0.17, 0.10, 0.12 0.23/0.24 1.40
Gd-DTPA 1 1 0.99 0.26/0.30 2.03
Gd-DOTMA 1 1 0.65 0.21/0.25 2.17
Gd-DTPA-BMA 2 0 0.34, 0.28 0.24/0.28 2.98
Gd-DOTA 2 0 0.53, 0.47 0.23/0.24 2.17
MAD, experimental phase information
was used during refinement in the form
of Hendrickson–Lattman coefficients
using the MLHL mode. For single-
wavelength data F+ and F were used
in MLF mode. The PDB codes of the
initial atomic protein models used for
refinement are 193l for lysozyme
(Vaney et al., 1996), 1ws3 for urate
oxidase (Retailleau et al., 2005), 1thw
for thaumatin (Ko et al., 1994), 1xib for
glucose isomerase (Carrell et al., 1994)
and 1k7k for YggV (Savchenko et al.,
2007), and the models corresponding to
the solved structures of YeaZ and CbpF
are PDB entries 1okj (Jeudy et al., 2005)
and 2v04 (Molina, Gonza´lez et al.,
2009), respectively. The progress of
refinement was followed using the Rfree
based on an excluded 5% of reflections.
All water molecules were removed from
the initial models. Initial values for
Gd-atom coordinates and occupancies
were obtained from SHARP phasing.
Rigid-body refinement, simulated
annealing and refinement of B factors
and of Gd-site occupancies were
followed by automatic introduction of
water molecules. The visualization of
electron-density maps and manual
adjustment of the models was
performed in O (Jones et al., 1991).
Experimental 2Fo  Fc and Fo  Fc electron-density maps
were used to model small molecules and ligands of the Gd
complexes. In the cases of Gd-DTPA-BMA (Ehnebom &
Pedersen, 1992), Gd-HPDO3A (Kumar et al., 1994), Gd-
DOTA (Dubost et al., 1991) and Gd-DO3A (Chang et al.,
1993), their known structures were used as initial models.
Gd-DOTMAwas modelled based on the Gd-DOTA structure,
adding methyl groups, and for Gd-DOTA-BOM the Gd-
DOTMA model was used, the additional (phenylmethoxy)
methyl group of the DOTA-BOM ligand being absent from
the electron-density maps. The CbpF Gd-DTPA derivative
allowed de novo construction of the model of Gd-DTPA. The
models of the complexes were adjusted manually using the
experimental and the Fo  Fc electron-density maps and were
included in refinement.
3. Results and discussion
3.1. Crystallization, data collection and phasing
Seven proteins, urate oxidase, lysozyme, thaumatin, glucose
isomerase, YggV, YeaZ and CbpF, have been used to prepare
derivative crystals with the seven different Gd complexes
which were then used for experimental phasing. Among these,
the structures of YeaZ and CbpF were effectively solved using
the complexes (Jeudy et al., 2005; Molina, Gonza´lez et al.,
2009). Generally, the derivatives were highly isomorphous to
the native crystals and the initial diffraction quality was
preserved.
Experimental phasing was carried out for all derivatives
that allowed determiniation of the complex-binding sites
(Supplementary Table S3). For about 50% of the tested
derivatives, binding-site occupancies of 0.3–1.0 allowed the
straightforward calculation of accurate experimental phases.
Table 2 summarizes the phasing results obtained with seven
systematically tested proteins, represented by the figures of
merit after density modification. In order to compare the
different derivatives among them and with other derivatiza-
tion methods (Table 1), we calculated the theoretical anom-
alous signal, F/F, provided by each derivative (Table 2),
where
F
F
ð%Þ ¼ 100
Zeff
2
P
q
j
2f
002
j
Np
 !1=2
¼ 0:76N1=2H qjf 00j ð1Þ
(Hendrickson & Ogata, 1997) assuming equal anomalous
binding-site occupancies qj; the average atomic scattering
factor of the native protein Zeff is 6.6 e
 for  = 0 and Np is the
number of protein atoms. Derivatives that allowed phasing
have minimum and maximum anomalous signals of 3.1 and
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Figure 2
Phasing results. (a) Bar graph representing the phasing success rate as a percentage for each
complex based on the derivatives described in Table 2. (b, c) Experimental electron-density map
after density modification (contoured at 1), our refined model (yellow sticks) and the original
incorrect model (magenta sticks). (b) Glucose isomerase Gd-DTPA derivative. The map clearly
shows the alternate conformations of Arg76. The side chain and water molecule in the original
model (PDB entry 1xib) are shown in magenta. (c) Urate oxidase Gd-DTPA-BMA derivative. The
inhibitor 8-azaxanthine in the refined model and the original orientation (PDB entry 1uox).
16% with data collected at the f 00 maximum, corresponding to
1.3 and 6.9% using Cu K radiation. By comparison, a sele-
nomethionine and a mercury derivative containing three
methionines and one fully occupied Hg site per 150 residues,
using data collected at the absorption edges, provide anom-
alous signals of 4.1 and 6.2%, respectively.
Overall, more than 50% (25 out of 44) of the tested deri-
vatives allowed successful phasing, as indicated by well
defined experimental electron-density maps, and for all of the
proteins at least two complexes provided suitable derivatives.
Fig. 2(a) represents the success rate for each complex, which
approximates to 50% for most complexes. Gd-DO3A proved
to be the most versatile, by binding to all of the proteins except
thaumatin, while Gd-HPDO3A only bound to lysozyme and
CbpF but provided the best derivatives in these cases.
The accurate experimental electron-density maps enable
straightforward bias-free structure determination and model
building. Notably, the alternate conformation of Arg76 and
two MPD molecules, which are very well defined in the
experimental map of our glucose isomerase derivative, are
absent in the original model, where they were modelled as
water molecules (Fig. 2b). Urate oxidase was crystallized in
the presence of its inhibitor 8-azaxanthin. Our experimental
electron-density map directly pointed out the wrong orienta-
tion of the inhibitor in the initial model (Fig. 2c). These
examples demonstrate how accurate experimental electron-
density maps allow direct, bias-free identification and
modelling of bound ligands, which can be crucial in drug
development.
3.2. Structure refinement and
binding-mode analysis
Generally, the extent to which
each complex bound was
different from one protein to the
next. The numbers and occu-
pancies of Gd-complex binding
sites varied, with multiple (four to
ten) binding sites of varying
occupancies in the case of Gd-
DO3A, three to eight sites for
Gd-DOTMA and between one
and three sites in the cases of the
other complexes (Table 3).
Binding sites are situated on the
protein surface or in solvent-
accessible cavities. They can
either vary from one complex to
the next, or complexes can share
the same binding sites, as is the
case for the major sites in certain
derivatives of lysozyme, thau-
matin or CbpF. The refined
structures of the bound
complexes in 21 different deriva-
tives gave insight into their
distinct binding modes (Table 4), which will be detailed below,
and explained the unequal binding behaviour with different
proteins.
In all of the complexes, the ligand arms carrying the func-
tional groups bend towards the Gd3+ ion, forming a cage
(Figs. 1d, 3, 4, 5, 6 and 7). The cyclen macrocycle forms the
hydrophobic back of the circular complexes, and the linear
ligands form a similar structure by folding onto themselves
(Fig. 6b). The circular back side can establish a CH–
hydrophobic interaction with aromatic residues of the protein
surface. Aromatic residues may also coordinate the sides of
certain complexes, forming an approximate plane (Figs. 5 and
7b). The N atoms of the back side and the O atoms of the
ligand arms, which are mainly negatively charged carboxylate
O atoms, coordinate the ion (Fig. 1). Thus, eight (or seven in
the case of DO3A) ligand atoms occupy the first coordination
sphere. In solution, the enneacoordination of the Gd3+ ion is
completed by one water molecule (two in the case of Gd-
DO3A; Fig. 1b). Contributing to complex binding, the Gd3+
ion can interact with the electronegative carboxylate or
carboxamide O atom of Asn, Gln, Asp or Glu, or with two
carboxylic O atoms in the case of the Gd-DO3A complex,
replacing the water molecules (GC; gadolinium coordination).
The Gd3+ ion can also coordinate a water molecule, which in
turn is coordinated by protein residues (iGC; indirect gado-
linium coordination). The outward-facing O atoms of the
ligand arms can accept hydrogen bonds (HB) or interact
electrostatically with positively charged protein residues, and
research papers
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Figure 3
Refined models of Gd complexes bound to urate oxidase. The cartoon representation of proteins is shown
in gold, or in grey for symmetry-related molecules. Only side chains of protein residues involved in complex
binding are shown. The ligands are shown as green sticks and the Gd3+ ion is shown as a magenta sphere.
(a, b, c) Binding of Gd-DTPA-BMA to urate oxidase. (a, b) Sites 1 and 2. (b) Refined 2Fo  Fc electron
density of protein and complex molecules at 1.45 A˚ resolution. (c) Binding site 3. (d) Major binding site of
Gd-DOTMA.
the DTPA-BMA amide N atoms can participate in hydrogen
bonds. The hydrogen-bond network between the ligand
functional groups and protein surface generally involves water
molecules of the hydration shell of the protein (W). In several
cases, interaction between two neighbouring complex mole-
cules contributes to their cooperative binding (CO; Figs. 3 and
7). Table 4 summarizes the types of interaction involved in
complex binding for the different derivatives. In order to
illustrate the observed binding modes, examples are described
for all of the complexes in more detail.
Of the three well phased urate oxidase derivatives (Table 2),
the Gd-DTPA-BMA and Gd-DOTMA derivatives allowed
refinement of the complex binding modes (Table 3). Gd-
DO3A binds at multiple sites with relatively low occupancies,
providing only poor electron density for the ligand molecules.
In this case, all of the complexes bound to different binding
sites. Binding sites 1 and 2 of the electrically neutral Gd-
DTPA-BMA are adjacent and are situated in the tunnel
formed by the tetramer of the protein. The molecules bind via
the coordination of the Gd ion by O atoms of the protein
surface (GC; Fig. 3a) and via hydrogen bonds between ligand
and protein atoms (HB) and water molecules, with six and
four refined water molecules bound to each ligand molecule
respectively (not shown) (W). The 2Fo Fc electron density of
the refined complex models is very well defined (Fig. 3b).
The third binding site is located in a cavity formed by two
symmetry-related protein molecules, and the ionic side of the
complex is turned towards the protein surface (Fig. 3c). In
contrast to sites 1 and 2, the Gd3+ ion is coordinated by a water
molecule (interaction type iGC), which forms two hydrogen
bonds to the protein surface. Binding also involves interaction
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Figure 4
Refined models of Gd-DO3A bound to glucose isomerase at site 1 (a) and
site 2 (b). Alternate conformations of protein residues involved in
complex binding were refined, corresponding to their conformations in
occupied (yellow) and empty (grey) complex-binding sites.
Figure 5
Major shared binding site of Gd-DOTMA (a) and of Gd-DO3A (b) in
YeaZ. Residues from three protein chains line the binding cavity.
Table 4
Observed types of interaction leading to complex binding.
Numbers in parentheses indicate the overall charge of the complex.
Abbreviations indicate the kind of observed interaction between the complex
molecule and the protein. GC, gadolinium coordination: interaction of the
Gd3+ ion with the carboxylate or carboxamide O atom of Asn, Gln, Asp or
Glu. iGC, indirect gadolinium coordination: the Gd3+ ion coordinates a water
molecule, which in turn is coordinated by protein residues. HB, hydrogen
bonds or electrostatic interaction between the ligand and protein residues. W,
hydrogen-bond network between the ligand and protein surface involving
water molecules of the hydration shell of the protein. CO, cooperative binding
of two neighbouring complex molecules.
Gd-HPDO3A (0)
CbpF CH–, iGC, HB, W
Lysozyme CH–, W, CO
Gd-DO3A (0)
CbpF GC, CH– ,W
YeaZ GC, CH–, HB
Lysozyme GC, CH–, W, CO
Glucose isomerase GC, HB, W
YGGV GC
Gd-DOTA (1)
Lysozyme CH–, GC, HB, CO
Thaumatin CH–, HB
CbpF CH–
Gd-DTPA-BMA (0)
Thaumatin CH–
Urate oxidase GC, HB, W
Gd-DOTA-BOM (1)
Lysozyme CH–, HB, W
Thaumatin CH–
Gd-DTPA (2)
CbpF GC, HB, W
Glucose isomerase iGC, HB, W
Thaumatin CH–, HB, W
Gd-DOTMA (1)
CbpF W
Urate oxidase CH–, HB, W
YeaZ GC, CH–, HB, W
YGGV W
Figure 6
Binding of four Gd complexes to thaumatin at the common binding site.
(a) Electrostatic surface representation of the protein monomer showing
the binding cavity, with the refined models of the complexes shown as
sticks. Red, Gd-DTPA-BMA; blue, Gd-DTPA; green, Gd-DOTA; yellow,
Gd-DOTA-BOM. The (phenylmethoxy)methyl group of Gd-DOTA-
BOM is not defined in the electron-density maps and therefore is not
included in the model. (b) Detailed binding mode of Gd-DTPA.
of the ligand with a surface lysine and an extensive network of
ordered water molecules. The almost fully occupied major
Gd-DOTMA binding site is situated in a shallow cavity
formed at the interface of two symmetry-related protein
molecules (Fig. 3d). The complex binds via a CH– interaction
between the complex macrocycle and an aromatic tryptophan
side chain. Interaction with a lysine and several water mole-
cules that are coordinated by the O atoms of the ligand and
the protein surface stabilize the binding (not shown). The
Gd3+ ion is turned towards the solvent.
In glucose isomerase, Gd-DTPA binds to a unique half-
occupied site via the coordination of a water molecule
between the Gd3+ ion and the protein surface and further
hydrogen bonds between the ligand and water molecules (not
shown). Gd-DO3A binds to six sites. In all sites a glutamate
or an aspartate is close to the ion as well as one or several
arginine residues, except at site 5. The refined structure of the
bound complex at three sites showed that the binding mode at
these sites is very similar. The complex binds through the
coordination of the Gd3+ ion by both carboxylate O atoms of
a glutamate residue situated on the protein surface (Fig. 4).
Hydrogen bonds between the carboxylate O atoms of the
ligand arms and the guanidinium N atoms of neighbouring
arginine residues (site 1 and 2) or tryptophan NE1 (site 3; not
shown) stabilize complex binding. The similarity of the protein
residues constituting binding sites 4 and 6 suggest a similar
binding mode as in the three major sites.
In YggV, Gd-DOTMA binds via hydrogen bonding invol-
ving a water network, while Gd-DO3A binds to multiple, less
occupied binding sites through direct coordination of the Gd
ion. In the YggV Gd-DOTA-BOM derivative all of the
binding sites have solvent-exposed aromatic residues in
proximity. Interaction between these residues and the phenyl
ring of the ligand possibly contributes to the binding of the
complex, although no electron density corresponding to the
phenyl group of the ligand is visible in any of the derivatives.
We previously solved the structure of E. coli YeaZ using
a Gd-DOTMA derivative (Jeudy et al., 2005). The protein
crystallizes with four molecules of 251 residues each per
asymmetric unit. The Gd-DOTMA and Gd-DO3A complexes
have their two major binding sites in common. The main site is
located in a cavity lined by residues from three protein chains
(Fig. 5). Binding of the complexes involves coordination of the
Gd ion by one and two carboxylic O atoms of an aspartate for
Gd-DOTMA and DO3A, respectively. Furthermore, in both
complexes one ligand carboxylate O atom interacts with
histidine NE2 and arginine NE, and the side of the complex
possibly interacts through CH– interaction with the adjacent
parallel tyrosine side chain.
In thaumatin, the Gd-DOTA-BOM, Gd-DTPA-BMA, Gd-
DOTA and Gd-DTPA complexes share their major binding
site, consisting of a cavity of about 14 A˚ in diameter and 11 A˚
in depth (Fig. 6a). All complexes bind through CH– inter-
actions between their cyclic back side and the parallel
aromatic side chain of Phe181. Their binding involves a
network of ordered water molecules between the ligand and
the protein surface, and additional hydrogen bonds for
Gd-DTPA (Fig. 6b) and Gd-DTPA-BMA. In the absence of
distinct interactions through the ligand arms, the electron
density of the arms is poorly defined, despite relatively high
binding-site occupancies, which is probably owing to a rota-
tional variation of the bound complexes.
In lysozyme, three of the complexes bind to two adjacent
sites (Table 4) situated in a cavity formed by three protein
molecules that is destined for binding the oligosaccharide
substrate (Fig. 7). Complex binding involves CH– inter-
actions of the cyclic back side, or the side formed by two ligand
arms, with side chains of tryptophan residues lining the cavity.
The larger Gd-DOTA-BOM complex only binds to one site.
The small size of the protein and the low solvent content of the
crystals (Table 2) possibly limit the number of alternative
binding sites. In all cases, binding of the adjacent molecules
is cooperative, involving the coordination of one Gd ion by
a carboxylate O atom of the neighbouring molecule or a
network of symmetric direct and water-mediated interactions
between the complex molecules (Figs. 7a and 7b). In addition,
aspartate residues coordinate the Gd ions of the Gd-DO3A
molecules (Fig. 7a), and ND2 of Asn103 hydrogen bonds to a
ligand carboxylate O atom of Gd-DOTA and Gd-DOTA-
BOM. Our accurate electron density of the Gd-HPDO3A
derivative allows the three carboxylated ligand arms to be
distinguished from that carrying the hydroxypropyl group,
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Figure 7
Binding of Gd-DO3A (a) and Gd-HPDO3A (b) to lysozyme at binding
site 1 (left) and binding site 2 (right). Dashed red and grey lines indicate
the interactions of the complexes with the protein or the adjacent
complex molecule and with water molecules, respectively.
which allowed us to correct the previously described orien-
tation (Girard et al., 2002).
We have previously solved the structure of CbpF using a
Gd-HPDO3A derivative (Molina, Gonza´lez et al., 2009) and
analysed the binding of five Gd complexes (Molina, Stelter et
al., 2009). Briefly, the C-terminal domain of CbpF is composed
of repeated 20-amino-acid CBMs, forming cavities lined by the
perpendicularly arranged aromatic rings of two or more
tryptophan residues and one tyrosine residue. Three of the
complexes bind through hydrophobic CH– interactions
between the complex macrocycle and the side chain of one of
the tryptophan residues shaping the choline-binding cavity.
In summary, several complexes were found to bind prefer-
ably to specific motifs. Thus, Gd-HPDO3A, Gd-DOTA-BOM
and Gd-DOTA were exclusively observed to bind through
CH– interactions with aromatic protein residues. The use of
the most versatile Gd-DO3A often provides derivatives with
multiple, partly occupied binding sites. Its binding generally
relies on the coordination of the Gd3+ ion by both carboxyl
O atoms of an aspartate or a glutamate, and is stabilized by
further optional interactions. Alternatively, binding of Gd-
DO3A via CH– interactions between the ligand macrocycle
and the aromatic cycle of tryptophan residues has been
observed. The complexes Gd-DTPA-BMA, Gd-DTPA and
Gd-DOTMA bind to proteins via varying modes.
4. Conclusions
The binding of seven Gd complexes in crystals of seven
proteins has been investigated. The preparation of the deri-
vatives by soaking or co-crystallization is rapid and is
nondisruptive to diffraction quality. The obtained derivative
crystals can be used for diffraction experiments using
synchrotron or in-house Cu K radiation. The in-house data
may serve to screen for complex binding or, in the case of
sufficiently well diffracting crystals, to determine the phases
and solve the structure, as performed for S. pneumoniae LytC
(Pe´rez-Dorado et al., 2010).
The complexes proved to be highly suitable for derivatiza-
tion by binding sufficiently for successful phasing in about
50% of the overall cases, and for each tested protein at least
two of the complexes allowed de novo phasing. The deriva-
tives are mostly isomorphous with the native structures, apart
from occasional side-chain movements owing to complex
binding. The complexes bind to the protein surface or acces-
sible cavities within the protein or formed by crystal stacking.
Different complexes bind via different binding modes
(Table 4) resulting from a combination of polar, electrostatic
and/or hydrophobic CH– interactions between the Gd ion,
ligand atoms and residues of the protein surface or the
hydration shell of the protein. Shape and charge comple-
mentarity contribute to binding, as the complexes are
observed to match their orientation to the surface shape and
negatively charged complexes bind to positively charged
surface regions more often than electrically neutral molecules.
Thus, binding depends in a complex manner on the chemical
structure of the complex, including its functional groups,
charge and size, and on the surface charge, topology and
exposed residues of the protein.
The observed binding modes explain the occasional influ-
ence of the complexes on the protein solubility. Their binding
to hydrophobic residues via CH– interaction may have a
solubilizing effect. Conversely, binding of the ionic side may
cover charged surface residues and expose the hydrophobic
complex back side, thus decreasing the protein solubility.
Depending on the protein, different complexes were
observed to bind to different sites or, in other cases, to share
binding sites and major types of interaction but with varying
complex orientations and binding-site occupancies owing to
differing additional interactions.
Generally, predicting complex-binding behaviour is not
straightforward. Complexes that are different in overall
charge, size and functional ligand groups may nevertheless
share common binding sites, as in the case of Gd-DO3A and
Gd-DOTMA binding to YeaZ. On the other hand, stereo-
chemically similar complexes can show entirely different
binding behaviour, as is the case for Gd-DOTMA and Gd-
DOTA-BOM, which differ only by the additional phenyl-
methoxy group, and Gd-HPDO3A and Gd-DOTA, which
differ by one methyl group. The intricate nature of complex
binding is particular striking for sites of CH– interaction,
where, depending on the protein, entirely different sets of
complexes bind (Table 5). This suggests that the type of
aromatic residue, its environment and possibly the chemical
conditions differently affect the tendency of each complex to
bind via CH– interactions.
We suggest that a promising approach for identifying a
suitable heavy-atom derivative for a new protein is to screen
three or more of the Ln complexes with observed comple-
mentary binding modes; for example, in a first round, Ln-
DO3A, Ln-HPDO3A and Ln-DTPA-BMA. In our case, using
this trio only would have provided good derivatives for all
seven test proteins (Table 2). In practice, screening implies
preparing derivative crystals via soaking or co-crystallization,
ideally in parallel with several complexes, the collection of at
least complete diffraction data using Cu K or synchrotron
radiation, data integration, inspection of anomalous Patterson
maps and possibly the detection of heavy-atom binding sites.
For proteins known to contain surface-accessible tryptophan
residues, Ln-HPDO3A should preferably be tested. For
proteins that bind choline, and other proteins that bind their
ligands through CH– interactions, Ln-HPDO3A and Ln-
DO3A are likely to bind.
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Table 5
Derivatives where complexes were observed to bind via CH–
interaction (indicated with a +).
Thaumatin Lysozyme CbpF Urate oxidase YeaZ
Gd-HPDO3A + +
Gd-DO3A + + +
Gd-DTPA +
Gd-DOTMA + +
Gd-DOTA + + +
Gd-DTPA-BMA + +
Gd-DOTA-BOM + + +
Table 1 shows a comparison of the anomalous scattering
properties and binding modes of conventional scatterers and
the described Ln complexes. It illustrates that by binding
through versatile binding modes and providing high anom-
alous scattering, the complexes constitute a useful comple-
ment to the classical heavy-atom screening compounds in the
crystallographer’s toolbox.
These complexes can be used for the develoment of new
methods such as serial femtosecond crystallography and, when
included in a screen, in combination with SAD phasing, for
high-throughput protein structure determination.
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